Back to results
US 9,074,223 B2Granted
Vectors and methods for transducing B cells
AssigneeImmusoft Corporation
InventorsMatthew Rein Scholz, Eric J. Herbig
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for transducing B cells. In particular, the present disclosure provides for vectors and methods for transducing resting B cells and methods for differentiating same to express a transgene of interest.
Claims15
A method for producing a protein of interest, comprising:
- (a) transducing in vitro a plurality of peripheral blood B cells with a retroviral vector pseudotyped with measles virus glycoproteins H and F to obtain a plurality of transduced B cells, wherein said retroviral vector comprises a nucleic acid of interest that encodes the protein of interest, the nucleic acid of interest being operably linked to a heterologous promoter that is capable of directing expression of the nucleic acid of interest in a plasma cell;
- (b) activating the plurality of transduced B cells to obtain a cell population comprising transduced B cells that have differentiated into CD38+ plasma cells, said step of activating comprising contacting the B cells with a composition comprising CD40L in combination with a B cell activating factor comprising one or more factors selected from IL-10, IL-4, IL-7, CpG DNA, IL-2, IL-15, IL-6, and IFN-α, wherein one of said factors is IL-15;
- and
- (c) culturing the CD38+ plasma cells of (b) so that the heterologous promoter directs expression of the nucleic acid of interest, and thereby producing the protein of interest.
1 more element
A method for producing a protein of interest, comprising:
- (a) activating in vitro a plurality of resting peripheral blood B cells to obtain a cell population comprising B cells that have differentiated into CD38+ plasma cells, said step of activating comprising contacting the B cells with a composition comprising CD40L in combination with a B cell activating factor comprising one or more factors selected from IL-10, IL-4, IL-7, CpG DNA, IL-2, IL-15, IL-6, and IFN-α, wherein one of said factors is IL-15;
- (b) transducing the cell population of (a) with a retroviral vector pseudotyped with measles virus glycoproteins H and F to obtain transduced CD38+ plasma cells, wherein said retroviral vector comprises a nucleic acid of interest that encodes the protein of interest, the nucleic acid of interest being operably linked to a heterologous promoter that is capable of directing expression of the nucleic acid of interest in a CD38+ plasma cell;
- and
- (c) culturing the transduced CD38+ plasma cells of (b) so that the heterologous promoter directs expression of the nucleic acid of interest, and thereby producing the protein of interest.
1 more element
Dependencies are inferred from the claim text.